Age at diagnosis, median, years | 56 (32–86) |
Age at metastatic disease, median, years | 60 (33–86) |
Gender, n (%) | |
Male | 35 (49.3) |
Female | 36 (50.7) |
Stage at diagnosis, n (%) | |
I/II | 19 (26.8) |
III | 24 (33.8) |
IV | 16 (22.5) |
Primary unknown | 12 (16.9) |
Origin of melanoma, n (%) | |
Cutaneous | 51 (71.8) |
Non-cutaneous | 20 (28.2) |
BRAF status, n (%) | |
Mutated | 34 (47.9) |
wt | 37 (52.1) |
Previous systemic therapy for metastatic disease, n (%) | |
Yes | 34 (47.9) |
No | 37 (52.1) |
Stage at metastatic disease*, n (%) | |
M1a | 14 (19.7) |
M1b | 9 (12.7) |
M1c | 31 (43.7) |
M1d | 17 (23.9) |
No of metastatic sites*, n (%) | |
1–2 | 39 (54.9) |
>3 | 32 (45.1) |
PS (ECOG)*, n (%) | |
0 | 32 (45.1) |
1 | 33 (46.5) |
2 | 6 (8.4) |
LDH, n (%) | |
1 xULN | 35 (49.3) |
2xULN | 28 (39.4) |
>2xULN | 7 (9.9) |
Unspecified | 1 (1.4) |
Best response, n (%) | |
ORR | 29 (40.8) |
DCR | 33 (46.5) |
CR | 8 (27.6) |
PD | 38 (53.5) |
PFS median, months | 4 |
OS median, months | 11 |
CR, complete response; DCR, disease control rate; ECOG, Eastern Cooperative Oncology Group ; LDH, lactate dehydrogenase; ORR, overall response rate; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PS, Performance Status; ULN, upper limit of normal.